Gilead Sciences | GILD - Operating Expenses

Stock Price
129.58
Daily Change
-2.48 -1.88%
Monthly
-6.47%
Yearly
26.42%
Q2 Forecast
128.61

Gilead Sciences reported $23.52B in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 538M Mar/2026
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
ALKERMES USD 1.75B 1.43B Mar/2026
Alnylam Pharmaceuticals USD 898.54M 66.78M Mar/2026
Amgen USD 4.78B 1.12B Mar/2026
Biogen USD 1.96B 69.6M Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Coherus Biosciences USD 51.83M 2.48M Dec/2025
Eli Lilly USD 10.02B 285M Mar/2026
Gilead Sciences USD 23.52B 18.55B Mar/2026
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
Glaxosmithkline GBP 9.17B 1.4B Dec/2025
Incyte USD 5.62B 4.5B Mar/2026
J&J USD 17.44B 1.53B Mar/2026
Merck USD 18.17B 8.01B Mar/2026
Moderna USD 1.78B 242M Mar/2026
Neurocrine Biosciences USD 599.9M 22.3M Mar/2026
Novartis USD 9.29B 507M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sanofi EUR 9.31B 1.2B Mar/2026
Sarepta Therapeutics USD 372.37M 480.65M Mar/2026
United Therapeutics USD 5.9B 5.1B Mar/2026
Vertex Pharmaceuticals USD 1.85B 78.6M Mar/2026